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ness of Growth Hormone Treatments in Europe) study as-
sembled cohorts of patients treated in childhood with re-
combinant human growth hormone (r-hGH) in 8 European 
countries since the first use of this treatment in 1984 and 
followed them for cause-specific mortality and cancer inci-
dence. Expected rates were obtained from national and local 
general population data. The cohort consisted of 24,232 pa-
tients, most commonly treated for isolated growth failure 
(53%), Turner syndrome (13%) and growth hormone defi-
ciency linked to neoplasia (12%). This paper describes in de-
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 Abstract 
 Background: The long-term safety of growth hormone 
treatment is uncertain. Raised risks of death and certain can-
cers have been reported inconsistently, based on limited 
data or short-term follow-up by pharmaceutical companies. 
 Patients and Methods: The SAGhE (Safety and Appropriate-
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tail the study design, methods and data collection and dis-
cusses the strengths, biases and weaknesses consequent on 
this.  Conclusion: The SAGhE cohort is the largest and longest 
follow-up cohort study of growth hormone-treated patients 
with follow-up and analysis independent of industry. It forms 
a major resource for investigating cancer and mortality risks 
in r-hGH patients. The interpretation of SAGhE results, how-
ever, will need to take account of the methods of cohort as-
sembly and follow-up in each country. 
 © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Background 
 Growth hormone (GH) treatment has been used since 
1957 to treat GH deficiency, and thereafter increasingly 
for short stature due to other causes. Initially, hormone 
extracted from human pituitaries (p-hGH) was used, and 
then since the mid-1980s synthetic recombinant human 
GH (r-hGH). Concerns about long-term safety were ini-
tially caused by an outbreak of Creutzfeldt-Jakob disease 
consequent on prion infection of pooled pituitaries used 
to produce human GH, whose use was therefore discon-
tinued in 1985. Subsequently, concerns were raised by re-
ports of apparent excesses of leukaemia  [1, 2] and other 
cancers  [3] , and more recently of mortality in France  [4, 
5] although not in three other SAGhE countries  [6] . There 
have been a number of studies investigating cancer and 
mortality risks in such patients  [7–22] , but these have 
limitations and leave considerable uncertainty.
 Although cohort studies have been published with tens 
of thousands of patients  [23–25] , these have been based on 
pharmaceutical company databases and very short follow-
up by physician reporting of adverse events. These data-
bases have produced much valuable information, but 
when used for cohort analyses, they provide uncertain ev-
idence on short-term effects (because of potential conflict 
of interest and potential incompleteness of outcome as-
certainment) and no evidence about the long term when, 
for instance, any cancers or other chronic disease risks 
consequent on treatment might be expected to manifest.
 Two cohort studies of patients treated with p-hGH 
have reported long-term follow-up: one study of 1,848 
UK patients followed for an average of 21 years  [26] and 
one of 6,107 US patients followed for an average of 17 
years  [27] . The dosage and timing of p-hGH treatment, 
however, is very different from that for r-hGH. The only 
published cohort studies of r-hGH patients not originat-
ing from follow-up in a pharmaceutical company data-
base have been of 360 cancer patients in the US followed 
for an unspecified period  [28] and 289 hypopituitarism 
patients in Sweden followed for an average of 5 years  [29] . 
The SAGhE (Safety and Appropriateness of Growth Hor-
mone Treatments in Europe) study was therefore initi-
ated in Europe to provide a large-scale international col-
laborative cohort study of r-hGH-treated patients with 
long-term follow-up for cancer incidence and mortality 
conducted independently of pharmaceutical companies. 
 This paper describes the rationale, design, recruitment 
and methods of the SAGhE cohort study and discusses its 
strengths and weaknesses. As well as conducting the co-
hort study of risks of mortality and cancer incidence de-
scribed here, the SAGhE project also investigated height 
and quality of life: the methods and interpretation of 
these components of SAGhE will be presented elsewhere.
 Patients and Methods 
 The study was of cohort design, conducted in 8 European 
countries, with the design and conduct coordinated from the out-
set and analyses centralised. The countries and data sources are 
shown in  table 1 . In brief, with appropriate ethics and privacy com-
mittee approvals, we attempted to identify in each country all res-
ident patients who were born before 1991–1995 (the exact year 
depending on the country), who had been treated with r-hGH at 
paediatric endocrine clinics at any time up to a date during 2007–
2009, depending on the country (or in France and Sweden up to 
1997) ( table 2 ), and who had never been treated with p-hGH. In 
Sweden and Germany, about 30% of the patients had been treated 
in clinical trials of GH, in France 10.5%, in Belgium and the Neth-
erlands about 7% or less, and in Italy, Switzerland, and the UK very 
few or none. In several countries (Belgium, Germany, Italy, the 
Netherlands, and the UK), the small proportion of patients receiv-
ing r-hGH because of chronic renal failure were sometimes or al-
ways registered in a different database from those treated for all 
other reasons, and identification of the renal patients was more 
sporadic and less complete than that of other patients. In Germa-
ny, national population-based identification was not practical, and 
identification was instead limited to patients meeting the above 
criteria from selected clinics. In Switzerland, ascertainment was 
clinic-based but covering most of the country, and in Italy, ascer-
tainment was population-based in part of the country and clinic-
based elsewhere. In Scotland, one clinic (Dundee) was not includ-
ed, but identification was otherwise population-based. In each 
country, the principle was followed that patients were included if 
ascertainment was either prospective (i.e. patients were identified 
as they started treatment) or if retrospective identification was 
close to 100% complete, so that recruitment could not be biased by 
the subsequent occurrence of cancers, deaths, etc. in cohort mem-
bers.
 In two countries, Germany and the UK, some patients included 
in the cohort were identified from pharmaceutical company post-
marketing surveillance registers. In Germany, these were registers 
of several companies (Lilly, Pfizer, Merck, Ferring, and Novo Nor-
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disk). In the UK, they were registers run by Kabi Pharmacia (now 
Pfizer), into which the treating physicians at all centres except one 
(Cardiff) had entered details of all patients treated at their centre, 
irrespective of the brand of r-hGH used for treatment. In both 
countries the registers were compiled at the time the patients start-
ed on GH, and hence before the study outcomes occurred; there-
fore, patient inclusion would not have been biased by outcome.
 Data were then extracted from existing databases and case 
notes ( table 3 ) on demographic variables, parental heights, birth 
characteristics, results of GH testing and additional endocrine 
deficiencies, and treatment of those deficiencies, at regular inter-
vals of height, weight, pubertal status, bone age, GH dose and 
number of weekly injections and associated treatments that 
might interfere with growth (sex steroids, GnRH agonists, ste-
roids), the use of cranial or total body irradiation, the diagnosis 
for which r-hGH was prescribed, and, in Belgium, France, Ger-
many, the Netherlands, Sweden, and Switzerland, cancers and 
deaths occurring during paediatric endocrine follow-up. Ascer-
tained subjects were then excluded from the cohort if their age at 
the start of treatment was outside the study criteria, or if their sex, 
 Table 1.  SAGhE study: sources of identification of GH-treated patients
Country Source of identification Population-
baseda or 
clinic-based
Identification (prospectiveb 
or retrospectivec)
Recording of GH
patients on database 
Estimated completeness 
of recruitmentd
Belgium National population-based 
register
Population-
based
Prospective Compulsory 98.4%
France National population-based 
register
Population-
based
Prospective Compulsory 100%
Germany National industry database for 
15 centres; clinical records as 
sole source for 1 centre and as 
additional source for 4 others 
(data in total from 16 of 70 
known centres)
Clinic-based Prospectively in industry 
database and retrospectively 
from clinicians
Voluntary Leipzig, Magdeburg, 
Tübingen, Dresden, and 
Rosenheim: 100%
Other centres: unknown, 
but recruitment entirely 
prospective
Italy Regional databases (Piedmont 
and Campania), National 
Institute of Health Register 
(18 of 20 Italian regions), 
clinical notes from 2 centres 
in Rome
Partly 
population- 
based (Piedmont 
and Campania 
and National 
Register); partly 
clinic-based
Prospective for databases
Retrospective from clinical 
notes
Voluntary Unknown, except 
Piedmont and 
Campania: 100%
Rome: near 100%
The 
Netherlands
National population-based 
register
Population-
based
Prospective Voluntary until 1997, 
compulsory after 
1997
About 95% nationwide 
until 1997, 100% after 
1997
Sweden National population-based 
register
Population-
based
Prospective Voluntary 99.5%
Switzerland National registries for 
children with chronic renal 
failure and cancer
Clinic databases and patient 
lists in 80% of Switzerland for 
all other diagnoses
Population-
based for renal 
failure and 
childhood 
cancer; clinic-
based otherwise
Prospective for patients with 
renal failure and childhood 
cancer
Retrospective as part of the 
SAGhE study for all other 
indications
Voluntary Near to 100% of patients 
nationally with chronic 
renal failure and cancer; 
near to 100% for all other 
diagnoses in 
participating centres
UK 
England
and Wales
National post-marketing 
surveillance study for all but 2 
centres 
Local clinical registries as sole 
source for 2 centres and as 
additional source for 2 others
Population-
based
Prospective Voluntary 100% in some centres
Others not known, but 
probably very high in 
post-marketing 
surveillance centres, less 
so in the 2 centres (of 21) 
using solely local 
registers
Scotland National post-marketing 
surveillance study
Clinic-based
(all clinics except 
Dundee)
Prospective Voluntary
a i.e. identified all subjects who live in a defined geographic area. b i.e. recorded on a register at time of first GH treatment. c e.g. identification made from 
existing case notes at the time of the SAGhE study. d i.e. percentage of patients treated in this population/clinic who were identified for the study.
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date of birth or date of starting treatment or ending follow-up 
was unknown, or if they were treated at centres where retrospec-
tive identification of cases was substantially incomplete or fol-
low-up was not possible.
 Follow-up of cohort members for incident cancers, deaths, em-
igrations, and other losses to follow-up was conducted by various 
methods depending on the country ( tables 4 ,  5 ). In Belgium, the 
Netherlands, Sweden, and the UK, there are national population-
based registries for vital status, follow-up, and cancer from which 
these data were obtained by record linkage. In the other countries, 
where such databases were not available, a range of sources were 
used including municipal registries, a national health insurance 
register, and questionnaires, as detailed in  tables 4 and  5 . In Bel-
gium, Switzerland, and the UK, all patients followed for mortality 
were also followed for cancer incidence except small numbers who 
did not reach the cancer incidence follow-up period. In the Neth-
erlands and Sweden, the situation was similar except for a small 
proportion of subjects who declined to be included. In the other 
countries, only subsets of subjects were included in cancer inci-
dence follow-up ( table 5 ): in Germany only patients at one centre 
were included; in France only patients whose initial diagnosis lead-
ing to GH treatment was not cancer, renal disease or certain other 
diseases (listed in  table 5 ) were included; and in Italy only those 
who returned questionnaires were included.
 Reported cancer diagnoses were validated by cancer registry 
data or from pathology reports, except in France where they were 
based on hospital records or coherence of other sources, and in 
Italy, where no validation was possible. In Belgium, Germany, the 
Netherlands, Sweden, Switzerland, and the UK, reported second 
cancers in patients whose initial diagnosis leading to GH treatment 
was cancer were rechecked for the SAGhE study to ensure that they 
were not restatements, recurrences or metastases of the original 
cancer. Because in Italy the ascertainment of cancer was retrospec-
tive and potentially highly biased, and there was no source of med-
ical validation of reported diagnoses, we will not include Italian 
subjects in cancer risk analyses; the numbers of Italian cancers by 
site will, however, be shown descriptively.
 Information about the cause of death was obtained from regis-
tries based on death certificates in most countries, supplemented 
by clinical notes in France and Germany, and was solely taken 
from clinical notes in the Netherlands.
 National cause-specific mortality data and population counts 
for the general population, to derive ‘expectations’ for mortality 
rates in the cohort, were obtained from death certificate-based sta-
 Table 2. SAGhE study: calendar periods of cohort entry and follow-up
Country Years of
starting GH 
treatment
Dates of mortality follow-upa Dates of cancer incidence follow-up
Belgium 1985 – 2009 First GH treatment – December 31, 2010 January 1, 1999 – December 31, 2008 
(Flemish region)
January 1, 2004 – December 31, 2008 
(Walloon and Brussels regions)
France 1985 – 1997 First GH treatment – September 21, 2009 January 1, 1985 – September 21, 2009
Germany 1985 – 2007 First GH treatment – February 28, 2010 
(except Tübingen: August 31, 2011)
January 1, 1985 – February 28, 2010
Italy 1985 – 2008 January 1, 1999 – December 31, 2009 January 1, 1985 – June 20, 2010 or February 
11, 2011, depending on when questionnaires 
for individuals were mailed
The 
Netherlands
1986 – 2007 First GH treatment – December 31, 2010 January 1, 1989 – December 31, 2011
Sweden 1985 – 1997 First GH treatment – December 31, 2010 January 1, 1985 – December 31, 2009
Switzerland 1986 – 2008 First GH treatment – December 31, 2010 January 1, 1985 – December 31, 2007, 
December 31, 2008, September 13, 2010, 
or December 31, 2011, depending on age 
and canton
UK 1984 – 2009 First GH treatment – September 30, 2013 
(England and Wales)
First GH treatment – December 31, 2013 
(Scotland)
January 1, 1984 – December 31, 2011 
(England and Wales)
January 1, 1984 – August 31 2011 
(Scotland)
 a Starting from the earliest GH treatment date (except Italy: January 1, 1999). The earliest use of r-hGH was in 1985 or 1986 in all 
countries except the UK, where the drug had first been used in trials in 1984.
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tistics from national statistics offices. National site-specific cancer 
incidence data, likewise, were obtained from national cancer reg-
istries (the Netherlands, Sweden, UK, and Belgium from 2004 on-
wards) or, where national cancer registration did not exist, from 
national estimates based on regional registry data (Belgium before 
2004, France, Germany, and Switzerland). The degree of diagnos-
tic detail available, for mortality and for cancer incidence statistics, 
varied between countries. Furthermore, non-malignant meningi-
omas (which constitute most meningiomas) were not included in 
German and French national cancer incidence statistics, and were 
not included in cancer incidence data for the Swiss r-hGH-treated 
cohort, so our analyses for meningioma incidence will exclude 
these countries.
 Person-years at risk of death will be calculated for each patient 
by sex, 5-year age-group, single calendar year, and country, start-
ing from the date of the first treatment with r-hGH and ending at 
whichever occurred earliest of death, loss to follow-up, or a fixed 
end date for each country (defined on the basis of the point to 
which follow-up in that country was considered complete at the 
time the follow-up data were obtained) ( table 2 ). Similar calcula-
tions will be conducted for cancer incidence, but with the date of 
cancer diagnosis as an additional end date for follow-up, and with 
a fixed end date for each country specific to the cancer incidence 
analyses ( table 2 ). In Switzerland, cancer incidence follow-up will 
be censored at age 16 or 21, depending on the canton, because the 
national cancer registry used to ascertain cancers occurring in the 
cohort only covered these ages.
 Observed numbers of cancers and deaths in the cohort will then 
be compared with expectations based on application of sex-, age-, 
country- and year-specific rates in the general population of each 
 Table 3. SAGhE study: sources of GH treatment data
Country Source of GH dataa GH data collected prospectivelyb or retrospectivelyc
Belgium National clinically run database Prospectively
France Yearly forms sent by clinical centres to a national 
agency until 1997; hospital case notes thereafter
Prospectively until 1997; thereafter retrospectively from 
hospital case notes in 3 sweeps (in 1999, 2001 and 2010)
Germany National industry database, clinical non-industry 
database, plus local clinic case notes
Prospectively in industry and clinical databases;
clinic notes retrospectively
Italy GH treatment registries (Piedmont and Campania); 
local clinic case notes and National Institute of 
Health Registry
National registry prospectively; clinic notes retrospectively
The 
Netherlands
Paediatric endocrinologists, hospital records, 
clinical notes
Prospectively, with missing data added retrospectively
Sweden National database independent of industry Prospectively in national database
Switzerland Original medical charts at centres of paediatric 
endocrinology, oncology, and nephrology
Retrospectively
UK National industry database plus local clinic case 
notes for a minority
Prospectively in industry database; retrospectively for 
hospital case notes
a i.e. doses, dates etc. for patients identified as GH-treated. b i.e. at the time of treatment. c i.e. extracted specially for SAGhE from 
existing case notes.
 Table 4. SAGhE study: sources of follow-up information on vital 
status
Country Source
Belgium National population registry that also 
records deaths, emigrations and other exits
France National civil status registry (RNIPP) and national 
health insurance registry (RNIAM)
No information on emigrations, but deaths abroad 
can be reported back to the French civil register
Germany Municipal registries and health authority registries 
for each region that record deaths, emigrations and 
other exits
Italy Deaths by linkage to national mortality database
The 
Netherlands
National database that records current and previous 
addresses, deaths, emigrations and other exits
Sweden National population register that records deaths, 
emigrations and other exits
Switzerland Questionnaire responses, where obtained; failing 
that, municipal registers that record deaths, 
emigrations and other exits; failing that, last clinic 
visit
UK National Health Service (NHS) Register that 
records deaths, emigrations and other exits
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country to the person-years at risk in these categories in the cohort, 
to derive standardised mortality ratios and standardised incidence 
ratios. Absolute excess rates will be calculated by subtracting the 
expected from the observed numbers of cases, dividing by person-
years at risk and multiplying by 10,000.
 Cancer and mortality risks will be analysed in the cohort over-
all and subdivided by dose and duration of GH treatment and by 
initial diagnosis for which patients received r-hGH. However, be-
cause the initial diagnosis of these patients heavily influences their 
future mortality and morbidity, and there were many different ini-
tial diagnoses, often with few cases per diagnosis, we devised 10 
categories of initial diagnosis leading to GH treatment and 4 larg-
er prognostically based groupings of initial diagnosis, which we 
will use in diagnosis-based analyses requiring larger numbers. The 
10 groups are shown in  table 6 . The 4 larger groups are Ia: isolated 
growth failure including isolated GH deficiency and idiopathic 
short stature, Ib: short stature in children born small for gesta-
tional age, II: multiple pituitary hormone deficiency, children with 
conditions/malformations associated with low or modest effects 
on mortality, chromosomal or syndromic conditions, benign pitu-
itary tumours, and III: high mortality conditions, including malig-
nancy, chronic renal failure, and chromosomal abnormalities at 
known high risk of cancer. Details are given in the online supple-
mentary material (see www.karger.com/doi/10.1159/000435856). 
These groupings were based on published evidence and clinical 
judgments about the prognosis of the individual diagnoses in gen-
eral, not in relation to GH treatment, and blind to the actual mor-
tality in the study or the outcomes of individual study subjects.
 Cohort Descriptive Variables 
 A total of 27,550 patients were identified who were 
treated with r-hGH in the study countries during the 
study period but not with p-hGH previously ( table 7 ). 
Twenty six of these were excluded from the cohort un-
 Table 5. SAGhE study: entry criteria and sources of follow-up information for cancer incidence analyses
Country Criteria for entry to follow-up for cancer 
incidence
Source(s) of follow-up information on 
cancer incidence
Followed 
for cancer 
incidence, n
Belgium All patients in the cohort National cancer registration; questionnaires to 
patients; clinical notes
1,345
France All patients except those with certain 
chronic diseases as the reason for GH 
treatmenta
Questionnaires to patients, hospital insurance 
records that hold data on hospital discharges and 
medicines used
Validation of diagnoses from hospital records when 
available; otherwise from coherence of diagnosis 
based on other sources
8,649
Germany Patients treated in Leipzig only Questionnaires to patients, hospital records, and 
Leipzig cancer registry
Validation of diagnoses from hospital pathology 
reports
559
Italy All patients in the cohort who replied to 
questionnaire
Questionnaires to patients
No validation of diagnoses
737
The
Netherlands
All patients in the cohort who did 
not decline to participate
National cancer registration 1,707
Sweden All patients in the cohort who did 
not decline to participate
National cancer registration 2,832
Switzerland All patients in the cohort National childhood cancer registration for ages 
<16 or <21 years depending on the canton
745
UK All patients successfully traced for 
follow-up at the NHS Central Registers
National cancer registration 3,902
Total 20,476
a Cancer, renal disease, syndromes with known high risk of cancer, acquired GH deficiencies, granulomatous diseases, total body 
irradiation, chemotherapy, bone marrow or solid organ transplantation.
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der analysis because they were first treated beyond the 
age of 19 years, 61 were excluded because their date of 
birth, sex or date of first treatment was unknown, and 
21 were excluded because their date of ending follow-up 
was unknown. In addition, in Germany, patients (n = 
19) from 3 centres were omitted because retrospective 
identification was only achieved for a small proportion 
of subjects from these centres; in the UK, 720 patients 
were omitted because of lack of permission for follow-
up or because the original anonymised database that had 
recorded the patients contained insufficient informa-
tion about these individuals to identify them for follow-
up; and in Italy, 2,471 patients were excluded because 
follow-up in that country was only possible from Janu-
ary 1, 1999 onward, and these patients had no follow-up 
beyond that date.
 This left 24,232 patients, 13,425 male and 10,807 fe-
male, who formed the study cohort for mortality analyses. 
For cancer incidence follow-up, a further 3,756 patients 
were excluded because of lack of permission or unavail-
ability of data, leaving 20,476 patients, 11,108 male and 
9,368 female, as the study cohort. Although these indi-
viduals will be included in the overall analyses, individu-
als who are missing data on more detailed variables, e.g. 
dose of GH, will be omitted from analyses of those par-
ticular variables. Descriptive characteristics of the cohort 
are shown in  table 7 . Most subjects started treatment at 
ages 10–14 years (51%) or 5–9 years (32%). Half (51%) 
were treated for isolated growth failure, 14% for Turner 
syndrome, 13% for GH deficiency linked to neoplasia and 
21% for other indications, although the proportions var-
ied considerably by country. Based on provocative GH 
stimulation tests where available to us, we estimate that 
76% of the patients with isolated growth failure had iso-
lated GH deficiency (maximum peak <10 ng/ml) and 24% 
had idiopathic short stature.
Table 6. Cohort by sex, age, year of treatment, diagnosis, and country
Belgium France Germany Italy The 
Netherlands
Sweden Switzerland UK  Total all 
countries
Sex
Male 645 (46.7) 5,800 (56.2) 1,027 (57.6) 852 (62.5) 847 ( 47.9) 1,773 (59.8) 406 (54.1) 2,075 (53.2) 13,425 (55.4)
Female 737 (53.3) 4,516 (43.8) 757 (42.4) 512 (37.5) 921 (52.1) 1,192 (40.2) 345 (45.9) 1,827 (46.8) 10,807 (44.6)
Age when GH treatment was started, years
0 – 4 144 (10.4) 704 (6.8) 116 (6.5) 33 (2.4) 191 (10.8) 310 (10.5) 72 (9.6) 451 (11.6) 2,021 (8.3)
5 – 9 382 (27.6) 3,114 (30.2) 553 (31.0) 327 (24.0) 624 (35.3) 1,099 (37.1) 266 (35.4) 1,395 (35.8) 7,760 (32.0)
10 – 14 716 (51.8) 5,428 (52.6) 957 (53.6) 886 (65.0) 788 (44.6) 1,366 (46.1) 363 (48.3) 1,756 (45.0) 12,260 (50.6)
15 – 19 140 (10.1) 1,070 (10.4) 158 (8.9) 118 (8.7) 165 (9.3) 190 (6.4) 50 (6.7) 300 (7.7) 2,191 (9.0)
Year when GH treatment was started
<1990 407 (29.5) 2,998 (29.1) 131 (7.3) 14 (1.0) 232 (13.1) 664 (22.4) 21 (2.8) 831 (21.3) 5,298 (21.9)
1990 – 1994 402 (29.1) 5,709 (55.3) 522 (29.3) 140 (10.3) 699 (39.5) 1,563 (52.7) 181 (24.1) 1,271 (32.6) 10,487 (43.3)
1995 – 1999 278 (20.1) 1,609 (15.6) 676 (37.9) 638 (46.8) 568 (32.1) 738 (24.9) 252 (33.6) 1,110 (28.4) 5,869 (24.2)
≥2000 295 (21.3) 0 (0.0) 455 (25.5) 572 (41.9) 269 (15.2) 0 (0.0) 297 (39.5) 690 (17.7) 2,578 (10.6)
Diagnosis leading to GH treatmenta
CNS tumour and 
craniopharyngioma 208 (15.1) 768 (7.4) 141 (7.9) 33 (2.4) 231 (13.1) 219 (7.4) 60 (8.0) 667 (17.1) 2,327 (9.6)
Other solid tumour 15 (1.1) 41 (0.4) 10 (0.6) 1 (0.1) 18 (1.0) 0 (0.0) 11 (1.5) 65 (1.7) 161 (0.7)
Hematological malignancy 41 (3.0) 280 (2.7) 12 (0.7) 6 (0.4) 63 (3.6) 77 (2.6) 6 (0.8) 251 (6.4) 736 (3.0)
Chronic renal failure and 
renal diseases 7 (0.5) 130 (1.3) 15 (0.8) 13 (1.0) 8 (0.5) 32 (1.1) 42 (5.6) 66 (1.7) 313 (1.3)
Turner syndrome 348 (25.2) 1,382 (13.4) 287 (16.1) 94 (6.9) 328 (18.5) 301 (10.2) 70 (9.3) 694 (17.8) 3,503 (14.5)
Other syndromes 
and chronic diseases 135 (9.8) 285 (2.8) 153 (8.6) 49 (3.6) 170 (9.6) 191 (6.4) 112 (14.9) 450 (11.5) 1,545 (6.4)
Multiple pituitary hormone
deficiency – organic GHD 153 (11.1) 884 (8.6) 220 (12.3) 30 (2.2) 328 (18.6) 269 (9.1) 100 (13.3) 513 (13.1) 2,497 (10.3)
Skeletal dysplasias 17 (1.2) 34 (0.3) 28 (1.6) 9 (0.7) 16 (0.9) 132 (4.5) 11 (1.5) 111 (2.8) 358 (1.5)
Isolated growth failure 458 (33.1) 6,476 (62.8) 913 (51.2) 1,109 (81.3) 585 (33.1) 1,545 (52.1) 333 (44.3) 1,049 (26.9) 12,468 (51.5)
Non-classifiable 0 (0.0) 36 (0.3) 5 (0.3) 20 (1.5) 22 (1.2) 199 (6.7)b 6 (0.8) 36 (0.9) 324 (1.3)
Total 1,382 10,316 1,784 1,364 1,768 2,965 751 3,902 24,232
Values are presented as numbers with percentages in parentheses. GHD = GH deficiency.
a Contents of the diagnostic categories are detailed in online supplementary table A1. b More in Sweden than elsewhere mainly because of subjects whose diagnosis was known to 
the registry but could not be disclosed to the SAGhE study because of lack of patient consent.
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 Follow-up for mortality was 96.7% complete, exclud-
ing data for Italy where completeness data were not avail-
able ( table 8 ). Follow-up for cancer incidence was 98.3% 
complete, excluding Italy and France where cancer inci-
dence ascertainment could not be conducted systemati-
cally. 
 Discussion 
 The published literature on risks of death and cancer 
incidence in relation to GH treatment is limited. Large 
cohorts of patients treated in childhood with r-hGH and 
recorded on pharmaceutical company databases have 
been followed for short periods  [5–7] , whereas longer fol-
low-up is limited to two cohorts of patients treated with 
p-hGH  [8, 9] , and two small cohorts of a few hundred r-
hGH patients each  [10, 11] .
 The SAGhE study has successfully assembled a cohort 
of r-hGH-treated patients with long-term follow-up on a 
far larger scale than has previously been reported: >24,000 
patients with >400,000 person-years of follow-up, an av-
erage of 17.1 years per patient. The combination of data 
from 8 countries enabled this scale of investigation, which 
is essential to gain the power to examine long-term risks. 
Inevitably, however, such an international aggregation 
involves overcoming complexities consequent on differ-
ences in clinical practice, and in the strengths and weak-
nesses of data, between countries. The initial recruitment 
of patients was population-based and near 100% com-
plete in Belgium, France, the Netherlands and Sweden. In 
Switzerland and the UK, recruitment was not quite as 
complete, but unlikely to be biased. In Switzerland there 
was near 100% ascertainment of patients at clinics cover-
ing about 80% of the country, except that for renal insuf-
ficiency and cancer as original diagnoses, the entire coun-
try was covered. In the UK, although a high proportion of 
patients had been recorded prospectively on a population 
basis, there was a 14% shortfall of patients whose identify-
ing details could not be determined retrospectively for 
follow-up from the non-identifying codes available on 
the national database. These losses through non-identifi-
ability were mainly at a few centres, but a comparison of 
descriptive characteristics and mortality of cohort mem-
bers at these centres and others in the UK did not suggest 
that the losses were biased. Mortality rates were very sim-
ilar in patients from high- and low-loss UK centres.
 In two countries, ascertainment of patients was more 
incomplete, with greater potential for bias. In Germany, 
identification was from a minority of clinics in the coun-
try, but in general these clinics had geographic catchment 
areas. In Italy, completeness of ascertainment was un-
known in all areas except Piedmont, Campania and 
Rome, and hence the extent of any bias in ascertainment 
was also unknown.
 The validity of the recorded information on the diag-
nosis leading to GH treatment may also have varied be-
tween countries. In several countries (Belgium, Italy, 
France, the Netherlands, Switzerland, and the UK), pre-
scription of GH was restricted, by regulation and/or re-
imbursement rules or clinical study protocols, to patients 
with certain diagnoses, and there was therefore potential 
 Table 7. SAGhE study: numbers of patients identified and exclusions from the cohort for mortality follow-up
Country Patients identified
as treated with
rGH
Clinics with incomplete 
retrospective
recruitment of
GH-treated patients
Date of birth
or sex
not known
Age ≥20 years
at the start of
GH treatment
Date when 
GH treatment
started unknown
Date of end 
of follow-up
not known
Follow-up
not possiblea
Total included
in cohort for
mortality
follow-up
Belgium 1,389 0 0 5 0 2 0 1,382
France 10,332 0 0 6 0 10 0 10,316
Germany 1,839 19 0 1 29 6 0 1,784
Italy 3,853 0 4 5 9 0 2,471a 1,364
The Netherlands 1,770 0 0 2 0 0 0 1,768
Sweden 2,971 0 0 4 0 2 0 2,965
Switzerland 754 0 0 0 2 1 0 751
UK 4,642 0 0 3 17 0 720a 3,902
Total 27,550 19 4 26 57 21 3,191 24,232
a Italy, no follow-up beyond the start of the follow-up period (January 1, 1999); UK, lack of identifier data (n = 671) or of permission 
(n = 47) or otherwise could not be followed (n = 2).
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
19
8.
14
3.
58
.1
 - 
2/
11
/2
01
6 
10
:3
9:
36
 A
M
 Swerdlow   et al.
 
 Horm Res Paediatr 2015;84:172–183 
DOI: 10.1159/000435856
180
for recorded diagnoses to be biased towards those for 
which GH treatment was permitted. In Germany, the 
Netherlands, Sweden, and Switzerland, we were able to 
use other information (e.g. case notes) to re-categorise 
the diagnoses for SAGhE, blind to outcomes. Interpreta-
tion of the results for each country will need to take ac-
count of the way in which diagnoses were obtained, and 
any potential biases in this, in that country.
 There was also variation between countries in the bal-
ance of diagnoses for which GH was prescribed. In Bel-
gium, the Netherlands and the UK, a particularly large 
proportion of patients had received GH after cancer. In 
France and Italy, a particularly large proportion of sub-
jects were reported as having isolated growth failure, and 
in Sweden there were also a large number with isolated 
growth failure and skeletal dysplasias because of clinical 
trials on these. It is notable that in France and Italy, the 
regulations/reimbursement rules gave an incentive to 
state this diagnosis for marginal cases, in order to be able 
to prescribe r-hGH, and the diagnostic labels stated at 
prescription were not reviewed using other information 
and re-categorised for the SAGhE study. The proportions 
of patients treated for chronic renal failure varied be-
tween countries, probably reflecting the separate and in-
complete identification of such patients in some coun-
tries, noted above. There was also variation in the sex ra-
tio of patients – a male excess in most countries, but not 
in Belgium and the Netherlands where females predomi-
nated: this reflected, in part at least, larger proportions of 
patients with Turner syndrome in these than in most oth-
er countries.
 The SAGhE countries varied in the years of first treat-
ment, and the years of follow-up, included in the study. 
This adds complexity to the analyses but does not, in 
principle, bias them. The cohort included both trial and 
non-trial patients, and where appropriate consideration 
will therefore need to be given to the potential differences 
in outcome that could occur between such patients. 
Countries varied also in the sources of information on, 
and likely completeness of follow-up for, vital status and 
cancer incidence. In Sweden, the UK, the Netherlands, 
Belgium except for cancer incidence before 2004, and 
Switzerland except for childhood cancer before 1991, fol-
low-up was via national registries (or in Switzerland a 
network of municipal registries) known to have virtually 
complete coverage of the resident population, virtually 
complete ascertainment of deaths, and high levels of com-
pleteness of national cancer registration. Mortality fol-
low-up in Germany is also believed to be complete, by 
tracking patients across residence registries in each re-
gion, but German cancer registration data were only 
available for the area around Leipzig, and hence cancer 
incidence analyses were limited to Leipzig patients and 
were likely to be incomplete if patients moved away from 
the Leipzig area. French mortality follow-up is over 99% 
complete, omitting small numbers of deaths abroad. 
 Table 8. SAGhE study: losses to follow-up for mortality and cancer incidence
Country Mortality Cancer incidence
emigrateda otherwisea 
lost 
total lost lost to follow-up 
(not by death) 
before end date, %
emigr ated otherwise
lost 
total lost lost to follow-up
(not by death or cancer) 
before end date, %
Belgium 32 4 36 2.6 18 0 18 1.3
France –b 421 421 4.1b – – –c –c
Germany 1 78 79 4.4 0 4 4 0.7
Italy – – –c –c – – –c –c
The Netherlands 38 19 57 3.2 38 19 57 3.3
Sweden 37 0 37 1.2 36 0 36 1.3
Switzerland 28 8 36 4.8 11 2 13 1.7
UK 31 53 84 2.2 20 35 55 1.4
Totald 167 162 750 3.3 123 60 183 1.7
Values presented are numbers unless otherwise stated. 
a Numbers attributed to emigration versus other reasons for loss to follow-up will depend on the quality of data available on reason 
for loss, as well as the extent of losses for different reasons. b No data available on emigrations, which are additional to the losses shown. 
c No data available on losses to follow-up. d Excluding Italy for mortality, and excluding Italy and France for cancer incidence.
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French cancer incidence data were based on several in-
complete sources including questionnaire responses, in-
surance records, and death certificate diagnoses, and 
were probably appreciably incomplete so will not be in-
cluded in risk analyses. In Italy, mortality follow-up was 
solely based on linkage to a national death register, with 
no method to ascertain emigrations and other losses to 
follow-up, and uncertainty about completeness of death 
ascertainment. Italian cancer incidence data, as noted 
earlier, were incomplete and not validated, so they will 
not be included in risk analyses.
 In addition to potential incompleteness of the follow-
up system, countries also differed in the extent to which 
follow-up needed to be censored when patients were 
known to have left the population covered by the system, 
e.g. because they emigrated. Such losses to follow-up be-
fore the cutoff end date constituted less than 5% of the 
cohort in all countries, except that in Italy follow-up was 
based on linkage to a death register with no information 
on losses, and therefore analyses had to assume no losses 
to follow-up before the end date, and in France there were 
unknown numbers of losses to follow-up from emigra-
tion, in addition to a 4.1% known loss to follow-up.
 Potentially, cancer and mortality risks in GH-treated 
patients could reflect the underlying condition leading to 
GH treatment, and the non-GH treatments given for this 
condition, as well as the effect of GH per se. One potential 
method to separate the effect of GH (if any) from that of 
the underlying diagnosis and its treatment would be to 
compare the GH-treated patients with other patients with 
the same condition who had not received GH. Such com-
parison data for untreated patients with the multiple un-
derlying diagnoses involved in SAGhE in 8 countries do 
not exist, however, and anyway this would not entirely 
solve the problem, since selective factors leading to GH 
treatment may themselves cause differences in cancer risk 
between treated and untreated groups. We have therefore 
elected, as in the great majority of GH cohort studies  [2, 
10, 11, 14, 15, 23–27] , to use general population rates as 
the main comparator for rates in the GH patients. These 
comparison data will have the strength of stability through 
large numbers, and well-documented and understood 
data sources, but the analyses need, as in previous co-
horts, to be interpreted carefully taking account that the 
comparison population did not have these diseases.
 Finally, in principle, the source of the diagnosis of the 
cause of death should be the same for the cohort as for the 
comparison population. All SAGhE countries used na-
tional population mortality registry data, based on death 
certificate diagnoses, for ‘expected’ rates in the study co-
hort, but only five countries used solely the same source 
to identify cause of death in the GH-treated cohort; in 
France and Germany, clinical notes as well as death cer-
tificates were used, and in the Netherlands only clinical 
notes were used.
 Overall, the uncertainties and weaknesses in the SA-
GhE data described above affect different countries for 
each facet of the data. Analyses and interpretation will 
therefore need to examine country-specific results as well 
as overall SAGhE results, and assess factors that might 
have influenced them (e.g. type of recruitment, extent of 
loss to follow-up), to check whether artefacts or biases 
might explain particular findings. We will analytically ag-
gregate data from groups of countries, and exclude groups 
of countries with potential biases or artefacts in common, 
to determine whether this affects the results: for instance, 
we will analyse together countries with higher quality of 
follow-up or diagnostic accuracy, and examine the effect 
on results for patients treated for isolated growth failure 
of excluding countries for which, as noted above, regula-
tions or reimbursement rules gave potential bias in re-
cording this diagnosis. Since France constitutes 42% of 
the total cohort, we will examine the extent to which the 
results for SAGhE overall are consequent on French re-
sults.
 The SAGhE cohort forms a major resource for inves-
tigating cancer and mortality risks in patients treated with 
r-hGH, now and in the future. With careful interpreta-
tion it should contribute greatly to determining whether 
this important treatment is safe.
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